PTC Therapeutics (NASDAQ:PTCT – Get Free Report) had its target price upped by research analysts at JPMorgan Chase & Co. from $72.00 to $78.00 in a research report issued to clients and investors on ...

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Friday after JPMorgan Chase & Co. raised their price target on the stock from $72.

PTC Therapeutics could boost revenue with vatiquinone for Friedreich's ataxia. Find out why PTCT stock is poised for growth ...

JPMorgan analyst Eric Joseph raised the firm’s price target on PTC Therapeutics (PTCT) to $78 from $72 and keeps an Overweight rating on the ...

Citi analyst Geoff Meacham raised the firm’s price target on PTC Therapeutics (PTCT) to $50 from $46 and keeps a Sell rating on the shares ...

Fintel reports that on March 11, 2025, B of A Securities upgraded their outlook for PTC Therapeutics (NasdaqGS:PTCT) from ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will participate in fireside chats at the following investor conferences: ...

Learn more about whether Exact Sciences Corporation or PTC Therapeutics, Inc. is a better investment based on AAII's A+ ...

The analysts might have been a bit too bullish on PTC Therapeutics, Inc. (NASDAQ:PTCT), given that the company fell short of expectations when it released its yearly results last week. PTC ...

Fintel reports that on March 11, 2025, B of A Securities upgraded their outlook for PTC Therapeutics (NasdaqGS:PTCT) from Underperform to Neutral. As of March 5, 2025, the average one-year price ...